3 159 227 159L227 159 227 159 227 159ZM230 160. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von lithium nmda receptors unabhängigen Gutachtern geprüft wurde. This is a preview of subscription content, log in to check access.

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. From maps to mechanisms through neuroimaging of schizophrenia. Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies.

Dopamine-glutamate interactions: a neural convergence mechanism of common schizophrenia risk variants. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Intracellular modulation of NMDA receptor function by antipsychotic drugs. Antidepressant effects of ketamine in depressed patients. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

TOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. New approaches to the pharmacological management of major depressive disorder. The neurobiology of schizophrenia: new leads and avenues for treatment.